The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher‐risk myelodysplastic syndromes
Open accessAbstract
BACKGROUND: In the AZA‐001 trial, azacitidine (75 mg/m 2/d subcutaneously for Days 1‐7 of every 28‐day cycle) demonstrated improved survival compared with conventional care regimens in patients with International Prognostic Scoring System‐defined intermediate‐2‐ or high‐risk myelodysplastic syndrome and World Health Organization‐defined acute myeloid leukemia with 20% to 30% bone marrow blasts. METHODS: This secondary analysis of the AZA‐001 phase 3 study evaluated the time to first response and the potential benefit of continued azacitidine treatment beyond first response in responders. RESULTS: Overall, 91 of 179 patients achieved a response to azacitidine; responding patients received a median of 14 treatment cycles (range, 2‐30). Median time to first response was 2 cycles (range, 1‐16). Although 91% of first responses occurred by 6 cycles, continued azacitidine improved response category in 48% of patients. Best response was achieved by 92% of responders by 12 cycles. Median time from first response to best response was 3.5 cycles (95% confidence interval [CI], 3.0‐6.0) in 30 patients who ultimately achieved a complete response, and 3.0 cycles (95% CI, 1.0‐3.0) in 21 patients who achieved a partial response. CONCLUSIONS: Continued azacitidine therapy in responders was associated with a quantitative increase in response to a higher response category in 48% of patients, and therefore may enhance clinical benefit in patients with higher‐risk MDS. Cancer 2011. © 2011 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Self-citationFenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70003-8 · Cited by 2,663 · cited 4×
“The international phase 3 trial AZA-001 established that the cytidine nucleoside analog azacitidine significantly prolonged median overall survival by >9 months and significantly delayed median time to AML transformation by >6 months compared with conventional care regimens.(3) Azacitidine was also associated with sig…”
MethodResultInfluentialSelf-citation
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Morschhauser, F., Tilly, H., Chaidos, A., McKay, P., Phillips, T., Assouline, S., Batlevi, C. L., Campbell, P., Ribrag, V., Damaj, G. L., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30441-1 · Cited by 604
Itzykson, R., Kosmider, O., Cluzeau, T., Mansat-De Mas, V, Dreyfus, F., Beyne-Rauzy, O., Quesnel, B., Vey, N., Gelsi-Boyer, V, Raynaud, S., et al. (2011) · Leukemia · doi:10.1038/leu.2011.71 · Cited by 471
Self-citationGounder, M., Schöffski, P., Jones, R. L., Agulnik, M., Cote, G. M., Villalobos, V. M., Attia, S., Chugh, R., Chen, T. W.-W., Jahan, T., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30451-4 · Cited by 427
Epigenetics in cancer stem cells
Toh, T. B., Lim, J. J., & Chow, E. K.-H. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0596-9 · Cited by 422
Metadata
- Authors
- Silverman, L. R., Fenaux, P., Mufti, G. J., Santini, V., Hellström‐Lindberg, E., Gattermann, N., Sanz, G., List, A. F., Gore, S. D., & Seymour, J. F.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2011-01-10
- Volume
- 117
- Issue
- 12
- Pages
- 2697-2702
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1513468396
- Cited by
- 194
- References
- 2
- FWCI
- 13.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher‐risk myelodysplastic syndromes. https://app.cochat.ai/papers/10.1002/cncr.25774
- The paper
- Silverman, L. R., Fenaux, P., Mufti, G. J., Santini, V., Hellström‐Lindberg, E., Gattermann, N., Sanz, G., List, A. F., Gore, S. D., & Seymour, J. F. (2011). Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher‐risk myelodysplastic syndromes. Cancer. https://doi.org/10.1002/cncr.25774
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.